Tenaya Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics for cardiovascular diseases. The company is headquartered in South San Francisco, California and currently employs 97 full-time employees. The company went IPO on 2021-07-30. Its pipeline includes TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy designed to deliver a working MYBPC3 gene to heart muscle cells via a single intravenous infusion, increasing MyBP-C protein levels to address the underlying cause of MYBPC3-associated HCM with the aim of halting or even reversing disease after a single dose. Its MyPEAK-1 Phase I b/2 clinical trial is an ongoing, multi-center, open-label, dose-escalating study designed to assess the safety, tolerability and clinical efficacy of a one-time intravenous infusion of TN-201 gene replacement therapy. TN-401 is its AAV9-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene.
Mr. Faraz Ali es el Chief Executive Officer de Tenaya Therapeutics Inc, se unió a la empresa desde 2018.
¿Qué tal es el rendimiento del precio de la acción TNYA?
El precio actual de TNYA es de $0.863, ha aumentado un 0.68% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Tenaya Therapeutics Inc?
Tenaya Therapeutics Inc pertenece a la industria Biotechnology y el sector es Health Care
¿Cuál es la capitalización bursátil de Tenaya Therapeutics Inc?
La capitalización bursátil actual de Tenaya Therapeutics Inc es $184.4M
¿Es Tenaya Therapeutics Inc una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 9 analistas han realizado calificaciones de análisis para Tenaya Therapeutics Inc, incluyendo 4 fuerte compra, 10 compra, 1 mantener, 0 venta, y 4 fuerte venta